What to Expect When Medicare and Pharma Finally Negotiate Drug Prices
The Inflation Reduction Act gave Medicare historic new power to directly negotiate the prices of some of the costliest prescription drugs. Now the federal agency must grapple with a difficult question: What makes a drug price fair?
This week, we explain how this negotiation process will work and the impact it could have.
Anton Avanceña, PhD, Assistant Professor of Health Outcomes, University of Texas
Darius Lakdawalla, PhD, Professor of Pharmaceutical Economics and Public Policy, University of Southern California
Lauren Neves, JD, Deputy Vice President, PhRMA
Steve Pearson, MD, MSc, Founder and President, Institute for Clinical and Economic Review (ICER)
Ben Rome, MD, MPH, physician and researcher, Harvard Medical School
Meena Seshamani, MD, PhD, Deputy Administrator, Centers for Medicare and Medicaid Services
Leslie Walker, Senior Producer/Reporter, Tradeoffs
Learn more and read a full transcript on our website.
Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.
Support this type of journalism today, with a gift.
Hosted on Acast. See acast.com/privacy for more information.